Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
ACADIA Pharmaceuticals Inc.
Type
Public
Traded as NASDAQ: ACAD
Industry Biopharmaceutical, Healthcare
Founded 1993
Headquarters San Diego, CA, U.S.
Key people
Stephen R. Davis
CEO
Products Pimavanserin
Revenue Increase $42.13M (2011)
Operating income
Increase $22.85M (2011)
Net income
Increase $22.76M(2011)
Total assets Increase 108.71M (2012)
Number of employees
95
Website

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase IV development as a treatment for Parkinson's disease psychosis. It is also developing AGN XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. The product candidates in the company's pipeline emanate from discoveries made using its proprietary drug discovery platform.

Acadia Pharmaceuticals extended its drug discovery and development research agreement with Allergan to March 2012. The agreement stipulates both parties will work together for the discovery of new therapeutics for glaucoma and ophthalmic conditions.

Investment goal date:
Dividends reinvested
ACADIA Pharmaceuticals Inc. ACAD report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-07
--
--
Q4 2017
2018-02-28
--
--
Q4 2017
2018-02-26
--
--
Q3 2017
2017-11-07
-0.5300
-0.5300
Q3 2017
2017-11-06
--
--
Q2 2017
2017-08-08
-0.5500
-0.5500
Q1 2017
2017-05-09
-0.7200
-0.7200
Q4 2016
2017-02-28
-0.6500
-0.6500
Q3 2016
2016-11-07
-0.6100
-0.6100
Q2 2016
2016-08-04
-0.6300
-0.6300
Q1 2016
2016-05-05
-0.4500
-0.4500
Q4 2015
2016-02-29
-0.4500
-0.4500
Q3 2015
2015-11-05
-0.3900
-0.3900
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BAKER BROS. ADVISORS LP
25819768
BlackRock Fund Advisors
2704309
BlackRock Inc.
5433209
BlackRock Institutional Trust Company, N.A.
2397396
Capital World Investors
2553000
FMR LLC
18211143
FRANKLIN RESOURCES INC
3656449
FRED ALGER MANAGEMENT INC
2180249
JANUS CAPITAL MANAGEMENT LLC
3418861
OPPENHEIMER FUNDS INC
4918286
PRICE T ROWE ASSOCIATES INC /MD/
4589871
Senator Investment Group LP
2000000
STATE STREET CORP
3237798
Vanguard Group, Inc
7469785
WADDELL & REED FINANCIAL INC
3091977
Major Shareholders
Name Relationship
Total Shares
Holding stocks
KAPLAN LESTER J PH D
0.0200% (17000)
ACAD /
BAKER FELIX
0.4400% (440802)
GRAY MARY ANN
0.1500% (149476)
BAKER BROS. ADVISORS LP
23.8400% (23708408)
Iversen Leslie L
0.0400% (36127)
ACAD /
Rasmussen Torsten
0.0100% (8500)
ACAD /
Hacksell Uli
0.1200% (115549)
ACAD /
Mills Roger
0.0200% (18550)
ACAD /
Moore Terrence O
0.0100% (9527)
ACAD / TSPT /
Baity Glenn
0.0700% (69656)
ACAD /
% ()